University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Jennifer R. Grandis, MD

Jennifer R. Grandis, MD

American Cancer Society Professor
Associate Vice Chancellor, Clinical and Translational Research
Director, Clinical and Translational Science Institute
Professor, Otolaryngology – Head and Neck Surgery, UCSF

Cancer Center Program Memberships

Tobacco Control | Experimental Therapeutics

Research Summary

I am Professor of Otolaryngology-Head and Neck Surgery and Associate Vice Chancellor for Clinical and Translational Research at UCSF, where I also direct the Clinical and Translational Science Institute (CTSI). My own research efforts are focused on elucidating and targeting key signaling pathways in head and neck cancer. I directed the head and neck cancer program at the University of Pittsburgh Cancer Institute from 1998-2014 and in this capacity facilitated collaborations between clinicians and investigators with an emphasis of developing a robust research infrastructure to support translational cancer studies. I served as PI of the SPORE in Head and Neck Cancer at the University of Pittsburgh from 2002-2014 and now serve as Co-PI of that SPORE in a multi-PI structure. I am a member of the Developmental Therapeutics Program at the HDFCCC and facilitate interactions between the cancer center and the CTSI.

Education

  • Swarthmore College, BA, Biology, 1982
  • Swarthmore College, BA, Art History, 1982
  • University of Pittsburgh, M.D., School of Medicine, 1987
  • University of Pittsburgh, Residency, School of Medicine, Surgery, 1988
  • University of Pittsburgh, Research Fellowship, School of Medicine, Infections Disease, 1992
  • University of Pittsburgh, Residency, School of Medicine, Otolaryngology, 1993

Professional Experience

  • 1987-1988
    Surgical Intern, University of Pittsburgh, Department of Surgery
  • 1988-1993
    Resident, University of Pittsburgh, Department of Otolaryngology
  • 1991-1992
    Research Fellow, University of Pittsburgh, Department of Medicine
  • 1993-1998
    Assistant Professor, University of Pittsburgh, Departments of Otolaryngology & Pharmacology (Secondary Appointment)
  • 1999-2004
    Associate Professor, University of Pittsburgh (with tenure)
  • 1998-2015
    Program Leader, Head & Neck Cancer Program, University of Pittsburgh Cancer Institute (UPCI)
  • 2004-2015
    Professor, University of Pittsburgh, Departments of Otolaryngology & Pharmacology (Secondary Appointment)
  • 2005-2015
    Vice Chair for Research, Department of Otolaryngology, University of Pittsburgh,
  • 2005-2015
    UPMC Endowed Chair in Head and Neck Cancer Surgical Research
  • 2010-2015
    Assistant Vice Chancellor for Research Program Integration in the Health Sciences, University of Pittsburgh,
  • 2012-2015
    Distinguished Professor of Otolaryngology, University of Pittsburgh
  • 2015- present
    Professor, Department of Otolaryngology - Head and Neck Surgery, UCSF
  • 2015- present
    Associate Vice Chancellor, Clinical and Translational Research Institute, UCSF

Honors & Awards

  • 1987
    University of Pittsburgh, School of Medicine, Kenneth H. Hinderer Award in Otolaryngology
  • 1987
    University of Pittsburgh, School of Medicine, Leo H. Criep, Award in Medicine,
  • 1986 University of Pittsburgh, Alpha Omega Alpha
  • 1982
    Swarthmore College, Oak Leaf Award
  • 2002
    American Society for Clinical Investigation, Elected Member
  • 2003
    University of Pittsburgh Cancer Institute, Scientific Leadership Award
  • 2005 -
    2014
    Pittsburgh Magazine, Top Doctor
  • 2008 -
    presAmerican Cancer Society, American Cancer Society Clinical Research Professorship
  • 2009
    University of Pittsburgh, Chancellor’s Distinguished Research Award
  • 2009
    MD Anderson Cancer Center, Waun Ki Hong Visiting Professorship
  • 2010
    University of Pittsburgh School of Medicine, Philip Hench Distinguished Alumnus Award
  • 2010
    Association of American Physicians, Elected Member
  • 2011
    University of Pittsburgh, Provost’s Award for Excellence in Mentoring
  • 2012
    The Ochsner Clinic Foundation, Alton Oschner Award Relating Smoking and Disease
  • 2012
    Institute of Medicine (IOM) of The National Academies, Elected Member
  • 2012
    University of Pittsburgh School of Medicine, Distinguished Professor of Otolaryngology
  • 2014
    University of Pittsburgh and Carnegie Mellon University, William E. Brown Outstanding MSTP Mentor Award, Medical Scientist Training Program
  • 2015
    Peggy Wheelock Award for Excellence in Research, Mentoring, and Promotion of Women in Science

Selected Publications

  1. Xu MJ, Johnson DE, Grandis JR. EGFR-targeted therapies in the post-genomic era. Cancer Metastasis Rev. 2017 Sep 02.
    View on PubMed
  2. El-Naggar AK, Chan JKC, Takata T, Grandis JR, Slootweg PJ. The fourth edition of the head and neck World Health Organization blue book: editors' perspectives. Hum Pathol. 2017 Aug; 66:10-12.
    View on PubMed
  3. Sun C, Fang Y, Yin J, Chen J, Ju Z, Zhang D, Chen X, Vellano CP, Jeong KJ, Ng PK, Eterovic AKB, Bhola NH, Lu Y, Westin SN, Grandis JR, Lin SY, Scott KL, Peng G, Brugge J, Mills GB. Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers. Sci Transl Med. 2017 May 31; 9(392).
    View on PubMed
  4. Sen M, Johnston PA, Pollock NI, DeGrave K, Joyce SC, Freilino ML, Hua Y, Camarco DP, Close DA, Huryn DM, Wipf P, Grandis JR. Mechanism of action of selective inhibitors of IL-6 induced STAT3 pathway in head and neck cancer cell lines. J Chem Biol. 2017 Jul; 10(3):129-141.
    View on PubMed
  5. Stabile LP, Egloff AM, Gibson MK, Gooding WE, Ohr J, Zhou P, Rothenberger NJ, Wang L, Geiger JL, Flaherty JT, Grandis JR, Bauman JE. IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer. Oral Oncol. 2017 Jun; 69:38-45.
    View on PubMed
  6. Kulkarni S, Bill A, Godse NR, Khan NI, Kass JI, Steehler K, Kemp C, Davis K, Bertrand CA, Vyas AR, Holt DE, Grandis JR, Gaither LA, Duvvuri U. TMEM16A/ANO1 suppression improves response to antibody-mediated targeted therapy of EGFR and HER2/ERBB2. Genes Chromosomes Cancer. 2017 Jun; 56(6):460-471.
    View on PubMed
  7. Ben-Dayan MM, Ow TJ, Belbin TJ, Wetzler J, Smith RV, Childs G, Diergaarde B, Hayes DN, Grandis JR, Prystowsky MB, Schlecht NF. Nonpromoter methylation of the CDKN2A gene with active transcription is associated with improved locoregional control in laryngeal squamous cell carcinoma. Cancer Med. 2017 Feb; 6(2):397-407.
    View on PubMed
  8. Li YY, Chung GT, Lui VW, To KF, Ma BB, Chow C, Woo JK, Yip KY, Seo J, Hui EP, Mak MK, Rusan M, Chau NG, Or YY, Law MH, Law PP, Liu ZW, Ngan HL, Hau PM, Verhoeft KR, Poon PH, Yoo SK, Shin JY, Lee SD, Lun SW, Jia L, Chan AW, Chan JY, Lai PB, Fung CY, Hung ST, Wang L, Chang AM, Chiosea SI, Hedberg ML, Tsao SW, van Hasselt AC, Chan AT, Grandis JR, Hammerman PS, Lo KW. Exome and genome sequencing of nasopharynx cancer identifies NF-?B pathway activating mutations. Nat Commun. 2017 Jan 18; 8:14121.
    View on PubMed
  9. Peyser ND, Grandis JR. Cancer genomics: Spot the difference. Nature. 2017 01 12; 541(7636):162-163.
    View on PubMed
  10. Brand TM, Hartmann S, Bhola NE, Peyser ND, Li H, Zeng Y, Isaacson Wechsler E, Ranall MV, Bandyopadhyay S, Duvvuri U, LaVallee TM, Jordan RCK, Johnson DE, Grandis JR. Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients. Clin Cancer Res. 2017 Jun 15; 23(12):3072-3083.
    View on PubMed
  11. Algazi AP, Grandis JR. Head and neck cancer in 2016: A watershed year for improvements in treatment? Nat Rev Clin Oncol. 2017 Feb; 14(2):76-78.
    View on PubMed
  12. Peyser ND, Pendleton K, Gooding WE, Lui VW, Johnson DE, Grandis JR. Genomic and Transcriptomic Alterations Associated with STAT3 Activation in Head and Neck Cancer. PLoS One. 2016; 11(11):e0166185.
    View on PubMed
  13. Kiesel BF, Parise RA, Guo J, Huryn DM, Johnston PA, Colombo R, Sen M, Grandis JR, Beumer JH, Eiseman JL. Toxicity, pharmacokinetics and metabolism of a novel inhibitor of IL-6-induced STAT3 activation. Cancer Chemother Pharmacol. 2016 Dec; 78(6):1225-1235.
    View on PubMed
  14. Lesseur C, Diergaarde B, Olshan AF, Wünsch-Filho V, Ness AR, Liu G, Lacko M, Eluf-Neto J, Franceschi S, Lagiou P, Macfarlane GJ, Richiardi L, Boccia S, Polesel J, Kjaerheim K, Zaridze D, Johansson M, Menezes AM, Curado MP, Robinson M, Ahrens W, Canova C, Znaor A, Castellsagué X, Conway DI, Holcátová I, Mates D, Vilensky M, Healy CM, Szeszenia-Dabrowska N, Fabiánová E, Lissowska J, Grandis JR, Weissler MC, Tajara EH, Nunes FD, de Carvalho MB, Thomas S, Hung RJ, Peters WH, Herrero R, Cadoni G, Bueno-de-Mesquita HB, Steffen A, Agudo A, Shangina O, Xiao X, Gaborieau V, Chabrier A, Anantharaman D, Boffetta P, Amos CI, McKay JD, Brennan P. Genome-wide association analyses identify new susceptibility loci for oral cavity and pharyngeal cancer. Nat Genet. 2016 Dec; 48(12):1544-1550.
    View on PubMed
  15. Bhola NE, Johnson DE, Grandis JR. A sensible approach to targeting STAT3-mediated transcription. Ann Transl Med. 2016 Oct; 4(Suppl 1):S57.
    View on PubMed
  16. Hartmann S, Grandis JR. Treatment of head and neck cancer in the elderly. Expert Opin Pharmacother. 2016 Oct; 17(14):1903-21.
    View on PubMed
  17. Zou AE, Zheng H, Saad MA, Rahimy M, Ku J, Kuo SZ, Honda TK, Wang-Rodriguez J, Xuan Y, Korrapati A, Yu V, Singh P, Grandis JR, King CC, Lippman SM, Wang XQ, Hinton A, Ongkeko WM. The non-coding landscape of head and neck squamous cell carcinoma. Oncotarget. 2016 08 09; 7(32):51211-51222.
    View on PubMed
  18. Hartmann S, Bhola NE, Grandis JR. HGF/Met Signaling in Head and Neck Cancer: Impact on the Tumor Microenvironment. Clin Cancer Res. 2016 Aug 15; 22(16):4005-13.
    View on PubMed
  19. Wang VE, Grandis JR, Ko AH. New Strategies in Esophageal Carcinoma: Translational Insights from Signaling Pathways and Immune Checkpoints. Clin Cancer Res. 2016 Sep 01; 22(17):4283-90.
    View on PubMed
  20. Bauman JE, Zang Y, Sen M, Li C, Wang L, Egner PA, Fahey JW, Normolle DP, Grandis JR, Kensler TW, Johnson DE. Prevention of Carcinogen-Induced Oral Cancer by Sulforaphane. Cancer Prev Res (Phila). 2016 Jul; 9(7):547-57.
    View on PubMed

Go to UCSF Profiles, powered by CTSI